Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response

Two patients with rare GCC2-ALK fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed unfavorable response to subsequent second or third generation tyrosine ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jing, Zeng, Daxiong, Xie, Fajun, Yu, Ruoying, Wu, Xue, Liu, Kaihua, Shao, Yang W., Lu, Hongyang, Jiang, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798362/
https://www.ncbi.nlm.nih.gov/pubmed/35116968
http://dx.doi.org/10.21037/tcr.2019.08.26
_version_ 1784641786821476352
author Qin, Jing
Zeng, Daxiong
Xie, Fajun
Yu, Ruoying
Wu, Xue
Liu, Kaihua
Shao, Yang W.
Lu, Hongyang
Jiang, Junhong
author_facet Qin, Jing
Zeng, Daxiong
Xie, Fajun
Yu, Ruoying
Wu, Xue
Liu, Kaihua
Shao, Yang W.
Lu, Hongyang
Jiang, Junhong
author_sort Qin, Jing
collection PubMed
description Two patients with rare GCC2-ALK fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed unfavorable response to subsequent second or third generation tyrosine kinase inhibitors (TKIs) treatment with shorten PFS. In conclusion, non-small cell lung cancer (NSCLC) patients with rare GCC2-ALK fusion G13:A20 may be optimal candidates for crizotinib as front-line therapy and may have a high possibility to exhibit unsatisfactory response to subsequent second or third generation TKIs target therapy after acquiring resistance to crizotinib.
format Online
Article
Text
id pubmed-8798362
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87983622022-02-02 Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response Qin, Jing Zeng, Daxiong Xie, Fajun Yu, Ruoying Wu, Xue Liu, Kaihua Shao, Yang W. Lu, Hongyang Jiang, Junhong Transl Cancer Res Brief Report Two patients with rare GCC2-ALK fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed unfavorable response to subsequent second or third generation tyrosine kinase inhibitors (TKIs) treatment with shorten PFS. In conclusion, non-small cell lung cancer (NSCLC) patients with rare GCC2-ALK fusion G13:A20 may be optimal candidates for crizotinib as front-line therapy and may have a high possibility to exhibit unsatisfactory response to subsequent second or third generation TKIs target therapy after acquiring resistance to crizotinib. AME Publishing Company 2019-09 /pmc/articles/PMC8798362/ /pubmed/35116968 http://dx.doi.org/10.21037/tcr.2019.08.26 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Brief Report
Qin, Jing
Zeng, Daxiong
Xie, Fajun
Yu, Ruoying
Wu, Xue
Liu, Kaihua
Shao, Yang W.
Lu, Hongyang
Jiang, Junhong
Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
title Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
title_full Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
title_fullStr Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
title_full_unstemmed Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
title_short Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
title_sort rare gcc2-alk fusion g13:a20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798362/
https://www.ncbi.nlm.nih.gov/pubmed/35116968
http://dx.doi.org/10.21037/tcr.2019.08.26
work_keys_str_mv AT qinjing raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT zengdaxiong raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT xiefajun raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT yuruoying raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT wuxue raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT liukaihua raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT shaoyangw raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT luhongyang raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse
AT jiangjunhong raregcc2alkfusiong13a20detectedbynextgenerationsequencinginnonsmallcelllungcancerpatientsandtreatmentresponse

Ejemplares similares